Doctor shopping reveals geographical variations in opioid abuse

Pain Physician

Volumn 16, Issue 1, 2013, Pages 89-100

  Nordmann, Sandra ^a   Pradel, Vincent ^a   Lapeyre Mestre, Maryse ^c   Frauger, Elisabeth ^a   Pauly, Vanessa ^b   Thirion, Xavier ^b   Mallaret, Michel ^d   Jouanjus, Emilie ^c   Micallef, Joëlle ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d Centre hospitalouniversitaire de Grenoble   (France)

Author keywords

Doctor shopping; Opioid abuse; Opioid maintenance treatments; Opioids for mild to moderate pain; Opioids for moderately severe to severe pain; Prescription drug abuse; Prescription drug database; Prescription opioid analgesics

Indexed keywords

BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; TRAMADOL;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DOCTOR SHOPPING; DRUG ABUSE; FEMALE; FRANCE; GEOGRAPHIC DISTRIBUTION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIOID ABUSE; PAIN; PRESCRIPTION; REIMBURSEMENT; SUSTAINED RELEASE FORMULATION;

FRANCE; HUMANS; OPIOID-RELATED DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRESCRIPTION DRUGS;

EID: 84872802087     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Manchikanti L, Helm S II, Fellows B, Janata J, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician 2012; 15; ES9-ES38.
2. Maxwell JC. The prescription drug epidemic in the United States: A perfect storm. Drug Alcohol Rev 2011; 30:264-270.
3. Brownstein JS, Green TC, Cassidy TA, Butler SF. Geographic information systems and pharmacoepidemiology: Using spatial cluster detection to monitor local patterns of prescription opioid abuse. Pharmacoepidemiol Drug Saf 2010; 19:627-637.
4. Cicero TJ, Surratt H, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007; 16:827-840.
5. Butler S, Budman S, Licari A, Cassidy T, Lioy K, Dickinson J, Brownstein J, Benneyan JC, Craig Green T, Katz N. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17:1142-1154.
6. Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, Woosley RL, Schulman KA. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res 2006; 41:837-855.
7. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006; 31:506-1051.
8. Smith MY, Irish W, Wang J, Haddox JD, Dart RC. Detecting signals of opioid analgesic abuse: Application of a spatial mixed effect poisson regression model using data from a network of poison control centers. Pharmacoepidemiol Drug Saf 2008; 17:1050-1059.
9. Gerada C, Ashworth M. ABC of mental health. Addiction and dependence--I: Illicit drugs. BMJ 1997; 315:297-300.
10. Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, Inciardi JA. Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues 2011; 41:283-304.
11. Fischer B, Bibby M, Bouchard M. The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: A review of sourcing routes and control measures. Addiction 2010; 105:2062-2070.
12. Inciardi JA, Surratt HL, Cicero TJ, Beard RA. Prescription opioid abuse and diversion in an urban community: The results of an ultrarapid assessment. Pain Med 2009; 10:537-548.
13. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club-and street-based populations. Pain Med 2007; 8:171-183.
14. Pradel V, Frauger E, Thirion X, Ronfle E, Lapierre V, Masut A, Coudert C, Blin O, Micallef J. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 2009; 18:36-43.
15. Cepeda MS, Fife D, Chow W, Mastrogiovanni G, Henderson SC. Opioid shopping behavior: How often, how soon, which drugs, and what payment method. J Clin Pharmacol 2012; In Press.
16. Cepeda MS, Fife D, Chow W, Mastrogiovanni G, Henderson SC. Assessing opioid shopping behaviour: A large cohort study from a medication dispensing database in the US. Drug Saf 2012; 35:325-334.
17. Martyres RF, Clode D, Burns JM. Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. Med J Aust 2004; 180:211-214.
18. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009; 181:891-896.
19. Simeone R., Holland L. An evaluation of prescription drug monitoring programs. 2006. Retrieved from http://pmpexcellence.org/pdfs/simeonepdmpeval2.2006.pdf.
20. Reisman, RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: An evaluation of state prescription drug monitoring program efficiency. Substance Abuse: Research and Treatment 2009; 3:41-51.
21. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine 2011; 12:747-754.
22. Baehren DF, Marco CA, Droz DE, Sinha SS, Callan EM, Akpunonu BS. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med 2010; 56:19-23.
23. Perrone J, Nelson LS. Medication reconciliation for controlled substances-an "ideal" prescription-drug monitoring program. N Engl J Med 2012; 366:2341-2343.
24. Worley J. Prescription drug monitoring programs, a response to doctor shopping: Purpose, effectiveness, and directions for future research. Issues Ment Health Nurs 2012; 33:319-328.
25. Pradel V, Thirion X, Ronfle E, Masut A, Micallef J, Bégaud B. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: Development of a new method for prescription database. Pharmacoepidemiol Drug Saf 2004; 13:473-481.
26. Pauly V, Frauger E, Pradel V, Nordmann S, Pourcel L, Natali F, Sciortino V, Lapeyre-Mestre M, Micallef J, Thirion X. Monitoring of benzodiazepine diversion using a multi-indicator approach. Int Clin Psychopharmacol 2011; 26:268-277.
27. Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M. Assessment of abuse potential of benzodiazepines from a prescription database using "doctor shopping" as an indicator. CNS Drugs 2010; 24:611-620.
28. Wilsey BL, Fishman SM, Gilson AM, Casamalhuapa C, Baxi H, Lin TC, Li CS. An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Monitoring Program. Pharmacoepidemiol Drug Saf 2011; 20:1262-1268.
29. Pauly V, Pradel V, Frauger E, Micallef J, Thirion X. Evolution of opioids reimbursement since 2004 from the National Database of the General Health Insurance System. Therapie 2011; 66:369-372.
30. De Conno F, Ripamonti C, Brunelli C. Opioid purchases and expenditure in nine western European countries: "Are we killing off morphine?". Palliat Med 2005; 19:179-184.
31. Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC. Increasing use of opioids from 2004 to 2007-pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010; 14:289-294.
32. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010; 58:286-290.
33. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2010. Oslo, 2009.
34. Rouby F, Pradel V, Frauger E, Pauly V, Natali F, Reggio P, Thirion X, Micallef J. Assessment of abuse of tianeptine from a reimbursement database using "doctor-shopping" as an indicator. Fundam Clin Pharmacol 2012; 26:286-294.
35. Ministère des Affaires sociales et de la Santé. Regional indicators collection. 2010. www.drees.sante.gouv.fr/recueild-indicateurs-regionaux-2010,1739.html. (Last accessed on May, 21, 2012).
36. Pauly V, Pradel V, Pourcel L, Nordmann S, Frauger E, Lapeyre-Mestre M, Micallef J, Thirion X. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend 2012; 126:13-20.
37. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011; 305:1346-1347.
38. Frauger E, Nordmann S, Orleans V, Pradel V, Pauly V, Thirion X, Micallef J. Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey. Fundam Clin Pharmacol. 2012; 26:549-556.
39. Nordmann S, Frauger E, Pauly V, Orléans V, Pradel V, Mallaret M, Thirion X, Micallef J. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. Pharmacoepidemiol Drug Saf 2012; 21:184-190.
40. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43:S197-S215.
41. McLellan AT, Turner B. Prescription opioids, overdose deaths, and physician responsibility. JAMA 2008; 300:2672-2673.